Loading stock data…
TEVA
$34.95-0.12 (-0.34%)
Market ClosedLast close May 1
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Teva Pharmaceutical Industries Limited in the Healthcare sector is trading at $34.95. The stock is currently near its 52-week high of $37.35, remaining 35.0% above its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why TEVA maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$34.95
Potential Downside
31.8%
Whystock Fair Value$23.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$40.09+14.7%
Range$31.00 – $50.00
Fundamentals
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$37.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
25.80
Beta
Defensive asset. Lower volatility than the S&P 500.
0.76
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.98%
Volume
Today's trading volume
5.00M
Recent News
Teva (TEVA) Enters a New $700 Million Acquisition Deal
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to acquire Emalex Biosciences. The transaction involves $700 million in cash, plus up to $200 million in milestone payments and royalties. Through the […]
Teva Pharmaceutical Industries Q1 Earnings Call Highlights
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued momentum in its innovative portfolio, while also outlining the company’s first acquisition under its “Pivot to Growth” strategy: the planned purchase of Amylyx and its Tourette syn
Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS Says
Teva Pharmaceutical Industries (TEVA) could see further upside as its valuation re-rates, supported
A Look At Teva (NYSE:TEVA) Valuation After Robust First Quarter 2026 Earnings Reaction
Earnings pop puts Teva’s latest quarter in focus Teva Pharmaceutical Industries (NYSE:TEVA) just released its first quarter 2026 results, with higher sales, net income and earnings per share compared with a year earlier, and the stock has reacted sharply. See our latest analysis for Teva Pharmaceutical Industries. The first quarter release has come after a period of strong gains, with a 24.8% 30 day share price return and a very large 1 year total shareholder return of 128.11%, which suggests...
TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up
Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.